Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Park

Showing results (31-40 of 50) with videos related to

Pageof 5
Sort By:
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
Blood|October 5, 2016
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S Ujjani, Sin-Ho Jung, Brandelyn Pitcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2019
Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphomaJason P Wong, Timothy J Stuhlmiller, Louise C Giffin, et al.
Leukemia & Lymphoma|June 12, 2019
Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphomaTarsheen K Sethi, Alexandra E Kovach, Natalie S Grover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphomaSteven I Park, Jaideep Shenoi, Shani M Frayo, et al.
Blood|May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Iscience|June 10, 2025
<i>TP53</i> upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in <i>BCL2-</i>rearranged lymphomasRajeswaran Mani, Samon Benrashid, Margaret D Templeton, et al.
Cancer|March 27, 2018
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapyI Brian Greenwell, Ashley D Staton, Michael J Lee, et al.
American Journal of Hematology|January 23, 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohortLapo Alinari, Alejandro Gru, Carl Quinion, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell LymphomaKevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Pageof 5

Showing results (31-40 of 50) with videos related to

Sort By:
Pageof 5
Blood|August 13, 2010
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual diseaseSteven I Park, Jaideep Shenoi, John M Pagel, et al.
Blood|October 5, 2016
Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103Chaitra S Ujjani, Sin-Ho Jung, Brandelyn Pitcher, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 27, 2019
Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphomaJason P Wong, Timothy J Stuhlmiller, Louise C Giffin, et al.
Leukemia & Lymphoma|June 12, 2019
Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphomaTarsheen K Sethi, Alexandra E Kovach, Natalie S Grover, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphomaSteven I Park, Jaideep Shenoi, Shani M Frayo, et al.
Blood|May 27, 2011
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft modelJohn M Pagel, Aimee L Kenoyer, Tom Bäck, et al.
Iscience|June 10, 2025
<i>TP53</i> upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in <i>BCL2-</i>rearranged lymphomasRajeswaran Mani, Samon Benrashid, Margaret D Templeton, et al.
Cancer|March 27, 2018
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapyI Brian Greenwell, Ashley D Staton, Michael J Lee, et al.
American Journal of Hematology|January 23, 2016
De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohortLapo Alinari, Alejandro Gru, Carl Quinion, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell LymphomaKevin R Kelly, Jonathan W Friedberg, Steven I Park, et al.
Pageof 5